Lenti-C2 CAR (scFv-BBζ, CIIC1; M2139)-VP (VP-CAR-LC45)

The ready-to-use lentiviral particles of Lenti-C2 CAR (scFv-BBζ, CIIC1; M2139)-VP is packaged using 3rd generation of lentiviral packaging system, in which the gene of CAR will be driven by a CMV promotor. The target gene of scFv (CIIC1; M2139)-41BB-CD3ζ packaged in lentiviral particles could be used for high efficency tranduction of T cells and stably integrated expression.

Datasheet   Add to Cart


  • Type of Therapeutics
  • Chimeric Antigen Receptor
  • Target
  • C2
  • Expression Cassette
  • scFv (CIIC1;M2139)-41BB-CD3ζ
  • Clone
  • CIIC1; M2139
  • Promotor
  • EF1a
  • Packaging System
  • Lentivirus
  • Packaging Cell
  • 293T
  • Targeting Diseases
  • Autoimmune arthritis


  • Introduction
  • Type II collagen is the basis for articular cartilage and hyaline cartilage.
    It makes up 50% of all protein in cartilage and 85-90% of collagen of articular cartilage.
    Type II collagen does form fibrils. This fibrillar network of collagen allows cartilage to entrap the proteoglycan aggregate as well as provide tensile strength to the tissue.
  • Alternative Names
  • C2; type II collagen; autoimmune arthritis; arthritis; scFv; FcεRIγ; Chimeric antigen receptor; T cell; Retrovirus; CARs; Lentivirus; chimeric T cell receptors; chimeric immunoreceptors; chimeric antigen receptors; CIIC1; M2139;CIIC1; M2139

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry


45-1 Ramsey Road, Shirley, NY 11967, USA
Call us at:
USA: 1-631-381-2994
Europe: 44-207-097-1828
Fax: 1-631-207-8356

Online Inquiry

For any technical issues or products/services related questions, please leave your contacts as below, and our team will contact you at earliest convenience to let you know how we can be involved in your projects.

  • Verification code

Key Updates

Receive the latest news and insights to your inbox.